Article Content

New clinical trials recently added to the National Cancer Institute's database

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

BLADDER CANCER

A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting

 

Phase: Phase III

 

Type: Diagnostic

 

Age: 18 and over

 

Trial IDs: PC B308/13, NCI-2015-01925, NCT02560584

 

Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: BOND 2 version 3.5, NCI-2015-01830, BOND 2 version 3.4, NCT02365818

 

Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 15-126, NCI-2015-01786, NCT02553642

 

BRAIN/CNS TUMORS

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102

 

Hippocampal-Avoiding Whole-Brain Radiotherapy with Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy in Treating Patients with Brain Metastases

 

Phase: Phase II

 

Type: Supportive care, Treatment

 

Age: 18 and over

 

Trial IDs: STU 042011-050, NCI-2015-01675, NCI-2014-01736, NCI-2014-02008, NCT01414738

 

Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 21 and under

 

Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397

 

Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

 

Phase: Phase II

 

Type: Treatment

 

Age: 21 and under

 

Trial IDs: NMTRC 003, NCI-2014-02153, NCI-2014-00474, NCT01586260

 

Radiosurgery in Treating Patients With Brain Metastases

 

Phase: Phase II

 

Type: Treatment

 

Age: Over 18

 

Trial IDs: 1306012291, NCI-2013-01986, NCT02005614

 

Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 12 months to 30 years

 

Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728

 

BREAST CANCER

Taselisib and Enzalutamide in Treating Patients with Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: VICC BRE 1374, NCI-2015-00795, BRE 1374, BRE 1374 / TBCRC 032, GO28972, TBCRC 032, NCT02457910

 

Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239

 

Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: BRS0050, NCI-2015-00036, 350, NCT02401347

 

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 19 and over

 

Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966

 

Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 2076-CL-005, NCI-2013-00059, NCT01639248

 

CERVICAL CANCER

A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348

 

COLORECTAL CANCER

Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 13050, NCI-2015-01790, NCT02425683

 

GI CANCERS

Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: ADXS001-06, NCI-2015-01897, NCT02399813

 

Docetaxel, Cisplatin, and Fluorouracil in Treating Patients with Gastric or Gastroesophageal Junction Cancer That is Metastatic or Cannot Be Removed by Surgery

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 06-103, NCI-2015-01798, NCT00515411

 

HEAD & NECK/ORAL CANCER

Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: D4193C00002, NCI-2015-01842, NCT02369874

 

Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer

 

Phase: Phase II

 

Type: Supportive care, Treatment

 

Age: 18 and over

 

Trial IDs: IOM-HNC-201-IL, NCI-2015-01924, NCT01400620

 

Radiation Therapy and Pembrolizumab in Treating Patients with Head and Neck Squamous Cell Carcinoma That Is Recurrent or Cannot Be Removed by Surgery

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 1456GCC, NCI-2015-01783, HP-00061458, NCT02289209

 

Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: TH-CR-602, NCI-2015-01845, NCT02449681

 

Paclitaxel Albumin-Stabilized Nanoparticle Formulation with Cisplatin or Cetuximab in Treating Patients with Stage III-IVb Head and Neck Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 201510013, NCI-2015-01775, NCT02573493

 

KIDNEY CANCER

Ixazomib Citrate and Peginterferon Alfa-2b in Treating Patients with Metastatic Kidney Cancer

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: GU-071, NCI-2015-01878, ERP GU-071, NCT02447887

 

LEUKEMIA/LYMPHOMA/MDS

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 17067, NCI-2015-01865, 2013-003893-29, NCT02367040

 

Azacitidine and Lenalidomide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: Over 18

 

Trial IDs: 12-1283, NCI-2012-03191, 12-1283.cc, RV-AML-PI-0759, NCT01743859

 

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CLBH589H2101, NCI-2010-00116, 2009-010548-32, NCT00946647

 

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride with Asparaginase in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 9459, NCI-2015-01402, CC9459, NCT02538926

 

Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small Lymphocytic Lymphoma

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: GS-US-313-1580, NCI-2015-01816, 2015-000366-66, NCT02536300

 

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: SGN35-025, NCI-2015-01867, NCT02572167

 

Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 to 79

 

Trial IDs: Onconova 04-30, NCI-2015-01849, 2015-001476-22, NCT02562443

 

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

 

Phase: Phase III

 

Type: Treatment

 

Age: 60 and over

 

Trial IDs: AG-221-AML-004, NCI-2015-01945, NCT02577406

 

Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: Over 18

 

Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140

 

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 45 and under

 

Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512

 

A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: ASN002-101, NCT02440685

 

Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 15 to 65

 

Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145

 

Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 1 and under

 

Trial IDs: TINI, NCI-2015-01493, NCT02553460

 

Ibrutinib and Rituximab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma or Older Patients with Newly Diagnosed Mantle Cell Lymphoma

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 2013-0090, NCI-2013-01304, NCT01880567

 

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: BL-8040.06, NCI-2015-01892, NCT02462252

 

LUNG CANCER/MESOTHELIOMA

A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer [IMpower 111]

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: GO29432, NCI-2015-01801, NCT02409355

 

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: HCRN LUN14-179, NCI-2015-01808, NCT02343952

 

A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CA209-451, NCI-2015-01840, NCT02538666

 

Irinotecan Hydrochloride in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: INST 1201, NCI-2012-01531, 12-097, NCT01607554

 

Nivolumab after Surgery and Chemotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: EA5142, NCI-2015-01916, NCT02595944

 

Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: TH-CR-601, NCI-2015-01844, NCI-2015-01843, NCT02454842

 

A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CO-1686-033, NCI-2015-01854, NCT02580708

 

MELANOMA/SKIN CANCER

Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: TH-CR-602, NCI-2015-01845, NCT02449681

 

Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 15-126, NCI-2015-01786, NCT02553642

 

MYELOMA

Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 to 65

 

Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662

 

Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 3475-183, NCI-2015-01850, 2015-002509-13, NCT02576977

 

Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 to 65

 

Trial IDs: BMTCTN1302, NCI-2015-01829, U01HL069294-05, NCT02440464

 

Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 3475-185, NCI-2015-01851, 2015-002901-12, NCT02579863

 

Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: Over 18

 

Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140

 

Pembrolizumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 1454GCC, NCI-2015-01784, GCC1454 / HP-00061522, HP-00061522, HCR-HP-00061522-1, NCT02289222

 

Monoclonal Antibody Therapy and Vaccine Therapy after Stem Cell Transplant in Treating Patients with Multiple Myeloma

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 09-061, NCI-2010-01326, NCT01067287

 

OVARIAN CANCER

A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: AL3818-US-001, NCI-2015-01926, NCT02558348

 

PANCREATIC CANCER

Cabozantinib-s-Malate in Treating Patients with Advanced Pancreatic Neuroendocrine or Carcinoid Tumors

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 11-274, NCI-2012-00539, NCT01466036

 

Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment

 

Age: 18 and over

 

Trial IDs: 1306012255, NCI-2013-02349, NCT02047474

 

Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: MCC-18141, NCI-2015-01782, 15.04.0041, NCT02575300

 

PROSTATE CANCER

Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients with Low- or Low-Intermediate-Risk Prostate Cancer

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Supportive care

 

Age: 40 to 75

 

Trial IDs: 9369, NCI-2015-00686, NCT02454517

 

Best Systemic Therapy with or without Radiation Therapy or Surgery in Treating Patients with Metastatic Prostate Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 2012-0705, NCI-2013-00415, NCT01751438

 

Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921

 

Sipuleucel-T and Stereotactic Ablative Body Radiation Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: STU 102012-026, NCI-2015-01669, NCT01818986